TICKERNERD
Menu
ELVELVHealthcare · Healthcare Plans

ELV Stock Forecast: Elevance Health, Inc. Price Predictions for 2026-2027

Last close, 14 Oct 2026
$428
+0.66% on the day

The 22 Wall Street analysts covering Elevance Health, Inc. hold a median 12-month price target of $463 — +8.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 73 of 100 as at 14 Oct 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$92.2B
Ticker Nerd rank
73 / 100
Median analyst target
$463
Analysts covering
22
Revenue$50.5B+1.4% y/y
Net income$1.5B
Free cash flow$1.6B
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+5.9%
1M
+0.9%
YTD
+23.9%
1Y
+24.6%
From 52W high
0.0%
From 52W low
+54.7%
$277
$428
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ELV stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Elevance Health, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Oct 2026
73 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
91
Value
90
Momentum
87
Revisions
80
Issuance
74
Growth
54
Quality
39
Accruals
38
Size
3

Volatility (91): The share price has been relatively steady.

Accruals (38): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (3): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ELV stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ELV, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$300$350$400$450$500Jan 26Apr 26Jul 26Oct 26ELVHigh $492Median $463Low $393

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says22 analysts
14 Buy8 Hold0 Sell
Low $393Median $463High $492

The green dot is the last close — the median target sits +8.2% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 8 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
12 Oct 2026GuggenheimMaintainsBuy$455 → $460
7 Oct 2026BarclaysMaintainsOverweight$457 → $469
17 July 2026BernsteinMaintainsOutperform—
17 July 2026BernsteinMaintainsOutperform$482 → $488
17 July 2026Leerink PartnersMaintainsMarket Perform—
17 July 2026Leerink PartnersMaintainsMarket Perform$364 → $395
16 July 2026BairdMaintainsNeutral$331 → $393
16 July 2026BairdMaintainsNeutral—
16 July 2026BarclaysMaintainsOverweight$480 → $457
16 July 2026BarclaysMaintainsOverweight—
16 July 2026GuggenheimMaintainsBuy—
16 July 2026GuggenheimMaintainsBuy$399 → $455
16 July 2026RBC CapitalMaintainsSector Perform$439 → $424
16 July 2026RBC CapitalMaintainsSector Perform—
16 July 2026Wells FargoMaintainsOverweight$492 → $473
16 July 2026Wells FargoMaintainsOverweight—
14 July 2026TD CowenMaintainsBuy$400 → $465
14 July 2026TD CowenMaintainsBuy—
14 July 2026Truist SecuritiesMaintainsBuy$450 → $475
14 July 2026Truist SecuritiesMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ELV appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ELV vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Oct 2026, Elevance Health, Inc. returned +24.6% against +17.5% for the S&P 500, dividends included.

ELV vs S&P 500, last 12 monthsTotal return, rebased to 100
8090100110120130Jan 26Apr 26Jul 26Oct 26ELVS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ELV analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+1.2%
Analysts raising
0
Analysts cutting
1
Fundamentals

Elevance Health, Inc. (ELV) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
18.8×

Cheaper than 39% of US stocks

Price / sales
0.5×

Cheaper than 83% of US stocks

Price / book
2.1×

Cheaper than 42% of US stocks

EV / EBITDA
10.3×

Cheaper than 36% of US stocks

Growth & margins
Revenue growth (YoY)
1.4%

Higher than 30% of US stocks

Earnings growth (YoY)
−16.1%

Higher than 23% of US stocks

Gross margin
—
Operating margin
4.6%

Higher than 54% of US stocks

Net margin
2.5%

Higher than 54% of US stocks

Returns & dividend
Return on equity
11.1%

Higher than 66% of US stocks

Return on assets
3.8%

Higher than 70% of US stocks

Dividend yield
1.6%

Higher than 76% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Elevance Health, Inc. (ELV) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Elevance Health, Inc. has a market value of $92.2B and an enterprise value of $85.9B.

  • Revenue in the twelve months to 30 June 2026: $201.1B. The latest quarter grew 1.4% year on year.

  • Net income over the same four quarters: $4.9B, a 2.5% net margin.

  • Diluted earnings per share, trailing twelve months: $22.50.

  • Free cash flow in the twelve months to 30 June 2026: $6.3B, after $1.2B of capital spending.

  • Elevance Health, Inc. spent $2.7B on share buybacks and $1.5B on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 216.8M.

  • Trailing P/E: 18.8×; forward P/E: 14.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 1.62%, paying out 30% of earnings.

  • Elevance Health, Inc. employs 96,129 people — $2.1M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 14 Oct 2026

Data provided by Twelve Data

Peers

ELV vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelHealthcare Plans
CompanyMarket capTKN rank
ELVElevance Health, Inc.$92.2B
73
CVSCVS Health Corp.$114.7B
86
CIThe Cigna Group$76.5B
75
HUMHumana, Inc.$51.4B
48
CNCCentene Corp.$34.5B
93
UNHUnitedHealth Group, Inc.$358.4B
78
MOHMolina Healthcare, Inc.$10.8B
36

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Elevance Health, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ELV news & analysis

ELV or DHR: Which Is the Better Value Stock Right Now?

Zacks Investment Research · 5 Oct 2026neutral

Zacks Investment Research published a comparison of Elevance Health (ELV) and Danaher (DHR) as potential value stocks, examining which of the two Medical Services sector stocks is more attractive to value investors.

Why it matters — The piece highlights how ELV is being evaluated by analysts on its value characteristics relative to a peer in the same sector, giving ELV watchers insight into its standing in value-investing comparisons.

Elevance Health to Hold Conference Call and Webcast to Discuss Third Quarter 2026 Results on October 21, 2026

Business Wire · 5 Oct 2026neutral

Elevance Health announced it will release its third quarter 2026 financial results on October 21, 2026 at 6:00 a.m. EDT, followed by a management conference call and webcast at 8:30 a.m. EDT that same morning to review results and outlook.

Why it matters — ELV watchers will know the exact date and time to tune in for the company's third-quarter earnings report and management's updated outlook.

Are Medical Stocks Lagging Elevance Health, Inc. (ELV) This Year?

Zacks Investment Research · 2 Oct 2026neutral

A Zacks Investment Research report compares the year-to-date performance of Elevance Health (ELV) and American Well Corporation (AMWL) against their sector. The article assesses whether medical stocks, including ELV, are lagging their sector peers this year.

Why it matters — ELV watchers would be interested in how the company's stock performance stacks up against both its sector and a comparable medical company, offering context on relative market standing.

Elevance Health's Affiliated 2027 Medicare Advantage Plans Advance Stability, Choice and More Coordinated Support

Business Wire · 1 Oct 2026positive

Elevance Health announced that its affiliated health plans will offer 2027 Medicare Advantage plans designed to help members navigate healthcare through more meaningful choice, simpler benefit experiences, and personalized support tailored to individual health needs.

Why it matters — The announcement signals Elevance's continued focus on its Medicare Advantage offerings, a key growth area that could affect member retention and plan competitiveness.

Are Medical Stocks Lagging Elevance Health, Inc. (ELV) This Year?

Zacks Investment Research · 16 Sept 2026neutral

Zacks Investment Research examines how Elevance Health (ELV) and American Well Corporation (AMWL) have performed versus their sector so far this year, with the headline questioning whether medical stocks are lagging Elevance Health.

Why it matters — ELV watchers would care about how the company's year-to-date performance compares with its sector and a peer, as such comparisons can signal relative strength or weakness.

FAQ

Frequently asked questions about ELV stock

What is the ELV stock price forecast for 2026-2027?

The 22 Wall Street analysts covering Elevance Health, Inc. have a median 12-month price target of $463, with estimates ranging from $393 to $492. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ELV stock a buy right now?

Of the 22 analysts covering Elevance Health, Inc., 14 rate it a Buy, 8 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Elevance Health, Inc. 73 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ELV?

As at 14 Oct 2026, Elevance Health, Inc. ranks 73 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (91 of 100).

Will ELV stock go up?

No one can know that. What the data says: the median 12-month target from 22 analysts implies +8.2% from the last close, and Ticker Nerd's factor model ranks Elevance Health, Inc. 73 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ELV stock forecast for 2030?

No analyst covering Elevance Health, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ELV are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $393 to $492 over the next 12 months.

How has ELV stock performed over the past year?

Elevance Health, Inc. returned +24.6% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Elevance Health, Inc. do?

Elevance Health, Inc. is a U.S.

What is the latest news on ELV?

The most recent item we track (Zacks Investment Research, 5 Oct 2026): "ELV or DHR: Which Is the Better Value Stock Right Now?". Zacks Investment Research published a comparison of Elevance Health (ELV) and Danaher (DHR) as potential value stocks, examining which of the two Medical Services sector stocks is more attractive to value investors.

Company

About Elevance Health, Inc.

Elevance Health, Inc. is a U.S. health benefits and health services company headquartered in Indianapolis, Indiana. It provides a broad range of health insurance products and related services for individuals, employers, and government-sponsored programs, with offerings that include commercial medical coverage, Medicare and Medicaid plans, dental, vision, behavioral health, and pharmacy benefits. The company operates through Health Benefits, CarelonRx, Carelon Services, and Corporate & Other, combining insurance operations with care management and healthcare enablement services. Elevance Health serves as a major participant in managed care, helping coordinate medical coverage, administrative services, and integrated care solutions across the U.S. healthcare system. Its portfolio is designed to support members, providers, and employer groups through a whole-health approach that links benefits, clinical support, and pharmacy services.

CEO Ms. Gail Koziara Boudreaux · 96,129 employees · United States · https://www.elevancehealth.com